



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

TGEN LICENSES METACORE FROM GENEGO

St. Joseph, Michigan, May 16th, 2005 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the Translational Genomics Research Institute (TGen) has licensed MetaCore™, GeneGo’s platform for mining of high-throughput experimental data in the context of human and mammalian “interactome” and common diseases. MetaCore is designed to process “genome scale” data files including microarrays and SAGE gene expression, proteomics and metabolomics. MetaCore applies multiple algorithms for generation, comparison and functional interpretation of biological networks and pathways.

“We evaluated MetaCore and decided that it was a good fit for TGen,” said Dr. Edward Suh, TGen’s Chief Information Officer. “GeneGo enables our scientists to generate global pathways and smaller targeted networks, and in addition, extending pathways and networks with GeneGo was a very attractive feature for gaining information.”

“We are very pleased to be working with TGen in aiding their mission to make and translate genomic discoveries into advances in human health that will have a direct impact on patients”, said Julie Bryant, VP of business development at GeneGo. “TGen has amassed an impressive group of experts in pre-clinical research and clinical trials that we plan to collaborate with.”

About

The Translational Genomics Research Institute (TGen) is a not-for-profit organization whose primary mission is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project to apply to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

TGen

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company’s original computational platform allows an integration and analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, siRNA and other phenotypic data) and relevant bioactive compounds (metabolites, drugs, ligands) within the framework of biological pathways and networks. GeneGo’s flagship product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation,

identification of biomarkers for disease states and toxicology. The second product, MetaDrugTM is designed for prediction of human metabolism and toxicity for novel small molecules compounds. MetaBaseTM represents the knowledge base for MetaCoreTM. For more information, please visit the company's web site at www.genego.com.

MetaCoreTM and MetaDrugTM are trademarks of GeneGo, Inc.